Literature DB >> 2297823

The complement system in ischemic heart disease.

M Yasuda1, K Takeuchi, M Hiruma, H Iida, A Tahara, H Itagane, I Toda, K Akioka, M Teragaki, H Oku.   

Abstract

The mechanisms by which tissue injury after acute myocardial infarction (AMI) occurs has not been fully elucidated. Recent evidence in experimental models has suggested involvement of the complement system in microvascular and macrovascular injury subsequent to AMI. With respect to angina pectoris, whether or not the complement system is activated is not clear. The present study assessed the role of complement as a mediator of myocardial inflammation by quantifying products of complement activation, including C3d, C4d, Bb, and SC5b-9 complexes, in 31 patients with AMI, 17 patients with unstable angina pectoris, 19 patients with stable angina pectoris, and 20 normal volunteers. The plasma C3d levels increased in patients with AMI and in those with unstable angina pectoris (p less than 0.01). The plasma levels of C4d, Bb, and SC5b-9 increased only in patients with AMI (p less than 0.01). The plasma SC5b-9 level was related to peak creatine phosphokinase (r = 0.71) and inversely related to the ejection fraction (r = -0.71). The plasma SC5b-9 level of patients with congestive heart failure was higher than that of patients without congestive heart failure in AMI. These results show that activation of complement system occurs after AMI and show an association of myocardial damage with complement activation. With respect to angina pectoris, the complement system is mildly activated in patients with unstable angina pectoris; however, the cardiac function of patients with unstable angina pectoris is not damaged. The complement system of patients with stable angina pectoris is not activated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297823     DOI: 10.1161/01.cir.81.1.156

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  25 in total

1.  Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction.

Authors:  T Tada; H Okada; N Okada; H Tateyama; H Suzuki; Y Takahashi; T Eimoto
Journal:  Virchows Arch       Date:  1997-04       Impact factor: 4.064

2.  Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model.

Authors:  B H M Heijnen; I H Straatsburg; N D Padilla; G J Van Mierlo; C E Hack; T M Van Gulik
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 3.  C-reactive protein as a pro-inflammatory mediator in cardiovascular disease by its ability to activate complement: additional proof and hypothetical mechanisms.

Authors:  W K Lagrand; R Nijmeijer; H W M Niessen; C A Visser; W Th Hermens; C E Hack
Journal:  Neth Heart J       Date:  2002-04       Impact factor: 2.380

4.  Serum complements and heart fatty acid binding protein in Bangladeshi patients with acute myocardial infarction.

Authors:  Nayareen Akhtar; Abu Taher; Rezwanur Rahman; Ashesh Kumar Chowdhury
Journal:  Heart Asia       Date:  2012-09-26

5.  Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.

Authors:  Shruti Chaturvedi; Noor Dhaliwal; Sarah Hussain; Kathryn Dane; Harshvardhan Upreti; Evan M Braunstein; Xuan Yuan; C John Sperati; Alison R Moliterno; Robert A Brodsky
Journal:  Blood Adv       Date:  2021-03-09

6.  Reduction of myocardial infarct size with sCR1sLe(x), an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x.

Authors:  K Zacharowski; M Otto; G Hafner; H C Marsh; C Thiemermann
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

7.  The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils.

Authors:  Enrico Lupia; Lorenzo Del Sorbo; Serena Bergerone; Giorgio Emanuelli; Giovanni Camussi; Giuseppe Montrucchio
Journal:  Immunology       Date:  2003-08       Impact factor: 7.397

Review 8.  Complement activity and pharmacological inhibition in cardiovascular disease.

Authors:  Pierre Théroux; Catherine Martel
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

9.  Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets.

Authors:  O A Hamad; K N Ekdahl; P H Nilsson; J Andersson; P Magotti; J D Lambris; B Nilsson
Journal:  J Thromb Haemost       Date:  2008-05-22       Impact factor: 5.824

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.